IP Library › Granted Patent US 12,502,428
Granted Patent B1
US 12,502,428 · App. 19/194,986 · Granted Dec 23, 2025

Immunotherapeutic composition for prevention of obesity, nonalcoholic fatty liver disease and hypertriglyceridemia, and methods of use and preparation thereof

Inventors: Uday Saxena (Hyderabad, IN); Gopi Kadiyala (Karnataka, IN)
Assignee: Utopia Therapeutics Pvt Ltd.
A61K39/385A61K9/0019A61K47/02A61P1/16A61P3/04A61P3/06A61K2039/54A61K2039/55505A61K2039/55561A61K2039/55577A61K2039/6037
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,502,428
App. No.
19/194,986
Granted
Dec 23, 2025
Kind
B1
Abstract

This disclosure provides a vaccine including a peptide with the amino acid sequence of SEQ ID NO:1; a nucleotide having the sequence of SEQ ID NO:2; or a ribonucleotide having the sequence of SEQ ID NO:3. In certain embodiments, the vaccine further comprises a buffer and/or an adjuvant.

Claims (13)

1 . A vaccine comprising:

a) a peptide consisting of the amino acid sequence of SEQ ID NO:1;

b) a nucleotide encoding the amino acid sequence of SEQ ID NO:1; or

c) a ribonucleotide encoding the amino acid sequence of SEQ ID NO:1.

2 . The vaccine of claim 1 , wherein the peptide is chemically modified.

3 . The vaccine of claim 1 , wherein the peptide is conjugated with an immunogenic protein or polyethylene glycol.

4 . The vaccine of claim 1 , wherein the quantity of the peptide ranges from about 0.1 mg to about 4.5 mg.

5 . The vaccine of claim 1 , wherein the peptide comprises at least a first D-amino acid.

6 . The vaccine of claim 1 , further comprising a buffer.

7 . The vaccine of claim 6 , wherein the buffer comprises phosphate-buffered saline (PBS).

8 . The vaccine of claim 1 , further comprising an adjuvant or a carrier protein.

9 . The vaccine of claim 8 , wherein the adjuvant is alum.

10 . The vaccine of claim 8 , wherein the quantity of the adjuvant ranges from about 0.1 ml to about 0.6 ml.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2025
From: SAXENA, UDAY; KADIYALA, GOPI
To: UTOPIA THERAPEUTICS PVT LTD
Reel/Frame 070988/0753 →
References Cited (20)
US 6288213B1 · Stahl et al. · 2001 [cited by applicant]
US 6657049B1 · Stahl · 2003 [cited by examiner]
US 11446398B2 · Barrett · 2022 [cited by examiner]
US 20030165430A1 · Shulman et al. · 2003 [cited by applicant]
US 20180318407A1 · Champion et al. · 2018 [cited by applicant]
WO 2017170494 · 2019 [cited by applicant]
WO 2021001804 · 2021 [cited by applicant]
Jean-Charles Fruchart, Raúl D. Santos, Carlos A. Aguilar-Salinas, Masanori Aikawa, Khalid Al-Rasadi, Pierre Amarenco, Philip J. Barter, et al.. “The selective peroxisome proliferator-activated receptor alpha modulator (… [cited by applicant]
Tomás Cerdó, José Antonio García-Santos, Mercedes García-Bermúdez, Cristina Campoy. “The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity”. Nutrients, 2019, https://doi.org/10.3390/nu11030635. [cited by applicant]
Behbahani, Sara. “The role of GLP-1 receptor agonist as a potential treatment for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis”. 2017, https://open.bu.edu/bitstream/2144/26621/5/Behbahani_bu_0017N… [cited by applicant]
Brennan, Paul N., Elsharkawy, Ahmed M., Fallowfield, Jonathan A., Kendall, et al.. “Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach”. 2023, https://core.ac.uk/download/573471505.d… [cited by applicant]
Banach, M., Surma, S., Toth, P.P. (2023) 2023: The year in cardiovascular disease—the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? Arch Med Sci. 19(6):1602-161… [cited by applicant]
Balling, M., Afzal, S., Davey Smith, G., Varbo, A., Langsted, A., Kamstrup, P.R., Nordestgaard, BG. (2023) Elevated LDL Triglycerides and Atherosclerotic Risk. J Am Coll Cardiol. 81(2):136-152. [cited by applicant]
Park, K.Y., Hong, S., Kim, K.S., Han, K., Park, C.Y. (2023) Trends in Prevalence of Hypertriglyceridemia and Related Factors in Korean Adults: A Serial Cross-Sectional Study. J Lipid Atheroscler. 12(2):201-212. [cited by applicant]
Ruiz-Garcia, A., Arranz-Martinez, E., López-Uriarte, B., Rivera-Teijido, M et al. (2020) Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study. Clin InvestigArterioscler. 32… [cited by applicant]
Krahenbuhl, S., Pavik-Mezzour, I., von Eckardstein, A. (2016) Unmet Needs in LDL-C Lowering: When Statins Won't Do! Drugs. 76(12):1175-90. [cited by applicant]
Heemskerk, M.M., van den Berg, S.A., Pronk, A.C., van Klinken, J.B., Boon, M.R., Havekes, L.M., Rensen, P.C., van Dijk, K.W., van Harmelen, V. (2014) Long-term niacin treatment induces insulin resistance and adrenergic … [cited by applicant]
Golanski, J., Szymanska, P., Rozalski, M. (2021) Effects of Omega-3 Polyunsaturated Fatty Acids and Their Metabolites on Haemostasis-Current Perspectives in Cardiovascular Disease. Int J Mol Sci. 22(5):2394. [cited by applicant]
Jakob, T., Nordmann, A.J., Schandelmaier, S., Ferreira-González, I., Briel, M. (2016) Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 11(11):CD009753. [cited by applicant]
Kazantzis, M., Stahl, A. (2012) Fatty acid transport proteins, implications in physiology and disease. BiochimBiophys Acta. 1821(5):852-7. [cited by applicant]